Hostname: page-component-77f85d65b8-g4pgd Total loading time: 0 Render date: 2026-03-26T18:27:12.251Z Has data issue: false hasContentIssue false
  • English
  • Français

A systematic review on the efficacy of GLP-1 receptor agonists in mitigating psychotropic drug-related weight gain

Published online by Cambridge University Press:  25 November 2024

Trisha Menon ,
Serene Lee ,
Xuan Yi Gong ,
Sabrina Wong ,
Gia Han Le ,
Angela T.H. Kwan ,
Kayla M. Teopiz ,
Roger Ho ,
Bing Cao Open the ORCID record for Bing Cao [Opens in a new window]  and
Taeho Greg Rhee
...Show all authors
Trisha Menon
Affiliation:
Brain and Cognition Discovery Foundation, Toronto, Ontario, Canada Department of Psychology, University of Toronto, Toronto, Ontario, Canada
Serene Lee
Affiliation:
Brain and Cognition Discovery Foundation, Toronto, Ontario, Canada Department of Health Sciences, Queen’s University, Kingston, Ontario, Canada
Xuan Yi Gong
Affiliation:
Brain and Cognition Discovery Foundation, Toronto, Ontario, Canada
Sabrina Wong
Affiliation:
Brain and Cognition Discovery Foundation, Toronto, Ontario, Canada Mood Disorder and Psychopharmacology Unit, University Health Network, Toronto, Ontario, Canada Department of Pharmacology & Toxicology, University of Toronto, Toronto, Ontario, Canada
Gia Han Le
Affiliation:
Brain and Cognition Discovery Foundation, Toronto, Ontario, Canada Mood Disorder and Psychopharmacology Unit, University Health Network, Toronto, Ontario, Canada Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada
Angela T.H. Kwan
Affiliation:
Brain and Cognition Discovery Foundation, Toronto, Ontario, Canada Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada
Kayla M. Teopiz
Affiliation:
Brain and Cognition Discovery Foundation, Toronto, Ontario, Canada
Roger Ho
Affiliation:
Department of Psychological Medicine, Yong Loo Lin School of Medicine, Singapore Institute for Health Innovation and Technology (iHealthtech), National University of Singapore, Singapore Division of Life Science (LIFS), Hong Kong University of Science and Technology (HKUST), Clear Water Bay, Hong Kong, China
Bing Cao
Affiliation:
Key Laboratory of Cognition and Personality, Faculty of Psychology, Ministry of Education, Southwest University, Chongqing, 400715, P. R. China
Taeho Greg Rhee
Affiliation:
Department of Psychiatry, Yale School of Medicine, New Haven, CT, USA Department of Public Health Sciences, University of Connecticut School of Medicine, Farmington, CT, USA
Yang Jing Zheng
Affiliation:
Brain and Cognition Discovery Foundation, Toronto, Ontario, Canada
Kyle Valentino
Affiliation:
Brain and Cognition Discovery Foundation, Toronto, Ontario, Canada
Kangguang Lin
Affiliation:
Department of Affective Disorder, The Affiliated Brain Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, Guangdong Province, China
Maj Vinberg
Affiliation:
Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark
Heidi K.Y. Lo
Affiliation:
Department of Psychiatry, School of Clinical Medicine, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China
Roger S. McIntyre*
Affiliation:
Department of Psychiatry, University of Toronto, Toronto, ON, Canada
*
Corresponding author: Roger S. McIntyre; Email: roger.mcintyre@bcdf.org
Get access Rights & Permissions [Opens in a new window]

Abstract

Objective

Many psychotropic drugs are highly associated with related weight gain. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are established anti-obesity and glucose-lowering agents. Preliminary evidence also indicates they are fit for purpose in mitigating psychotropic drug-related weight gain (PDWG). This systematic review aims to synthesize the extant evidence from randomized controlled trials (RCTs) on the effects of GLP-1RAs on weight change in persons experiencing PDWG.

Methods

Online databases (ie, PubMed, OVID Medline, Google Scholar) were searched to identify relevant studies from inception to January 1, 2024. Articles were screened by title, abstract, and full-text by three independent reviewers against inclusion and exclusion criteria.

Results

We identified six studies with participants aged ≥18 (n=374) that were eligible for inclusion in our systematic review. Most studies reported a significant and clinically meaningful effect of GLP-1RAs on anthropometrics and/or metabolics. All RCTs replicated the finding of modest or greater effects of GLP-1RAs; the most studied agents were liraglutide and exenatide. There was insufficient literature to conduct a meta-analysis.

Conclusion

Evidence suggests that GLP-1RAs are effective in mitigating weight gain in persons prescribed psychiatric medication. It is hypothesized that GLP-1RAs may moderate weight change in persons prescribed psychiatric medication through direct effects on metabolism and cognitive processes implicated in hunger/satiety. Future studies should aim to explore the long-term safety, tolerability, and efficacy profiles of various GLP-1RAs in the treatment and prevention of abnormal weight and metabolic homeostasis in psychiatric populations.

Keywords

schizophreniapsychotropic drug-related weight gainglucagon-like peptide-1 receptor agonistliraglutideexenatidedepressionbipolar disorderGLP-1dulaglutidesemaglutide

Information

Type
Review
Information
CNS Spectrums , Volume 29 , Issue 5 , October 2024 , pp. 347 - 353
Copyright
© The Author(s), 2024. Published by Cambridge University Press

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable

Footnotes

T.M., S.L., and X.Y.G. denotes co-first authorship.

This article has been updated since it was originally published. A notice detailing this has been published.

References

McIntyre, RS, Kwan, ATH, Rosenblat, JD, Teopiz, KM, Mansur, RB. Psychotropic drug–related weight gain and its treatment. The American Journal of Psychiatry 2024;181(1):26–38. doi:10.1176/appi.ajp.20230922CrossRefGoogle ScholarPubMed
Pillinger, T, McCutcheon, RA, Vano, L, et al. Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: A systematic review and network meta-analysis. The Lancet Psychiatry 2020;7(1):64–77. doi:10.1016/s2215-0366(19)30416-xCrossRefGoogle ScholarPubMed
Liu, Y, Ling, S, Lui, L, et al. Prevalence of type 2 diabetes mellitus, impaired fasting glucose, general obesity, and abdominal obesity in patients with bipolar disorder: A systematic review and meta-analysis. Journal of Affective Disorders 2022;300:449–461. doi:10.1016/j.jad.2021.12.110CrossRefGoogle ScholarPubMed
Jawad, MY, Meshkat, S, Tabassum, A, et al. The Bidirectional Association of nonalcoholic fatty liver disease with depression, bipolar disorder, and schizophrenia. CNS Spectrums 2022;28(5):541–560. doi:10.1017/s1092852922001043CrossRefGoogle Scholar
Najar, H, Joas, E, Jonsson, V, Pålsson, E, Landén, M. Recent secular trends of Body Mass Index in individuals with bipolar disorders and in the general population. The American Journal of Psychiatry 2024;181(1):39–46. doi:10.1176/appi.ajp.20230012CrossRefGoogle ScholarPubMed
McElroy, SL, Keck, PE. Obesity in bipolar disorder: An overview. Current Psychiatry Reports 2012;14(6):650–658. doi:10.1007/s11920-012-0313-8CrossRefGoogle ScholarPubMed
Taylor, VH, McIntyre, RS, Remington, G, Levitan, RD, Stonehocker, B, Sharma, AM. Beyond pharmacotherapy: Understanding the links between obesity and chronic mental illness. The Canadian Journal of Psychiatry 2012;57(1):5–12. doi:10.1177/070674371205700103CrossRefGoogle ScholarPubMed
Fagiolini, A, Kupfer, DJ, Houck, PR, Novick, DM, Frank, E. Obesity as a correlate of outcome in patients with bipolar I disorder. The American Journal of Psychiatry 2003;160(1):112–117. doi:10.1176/appi.ajp.160.1.112CrossRefGoogle ScholarPubMed
Nigatu, YT, Reijneveld, SA, de Jonge, P, van Rossum, E, Bültmann, U. The combined effects of obesity, abdominal obesity and major depression/anxiety on health-related quality of life: The lifelines cohort study. PLoS ONE 2016;11(2). doi:10.1371/journal.pone.0148871CrossRefGoogle ScholarPubMed
McIntyre, RS. The co-occurrence of depression and obesity. The Journal of Clinical Psychiatry 2024;85(2). doi:10.4088/jcp.24com15322CrossRefGoogle ScholarPubMed
Daumit, GL, Dickerson, FB, Wang, N-Y, et al. A behavioral weight-lossintervention in persons with serious mental illness. The New England Journal of Medicine 2013;368(17):1594–1602. doi:10.1056/nejmoa1214530CrossRefGoogle ScholarPubMed
Allison, DB, Mentore, JL, Heo, M, et al. Antipsychotic-induced weight gain: A comprehensive research synthesis. The American Journal of Psychiatry 1999;156(11):1686–1696. doi:10.1176/ajp.156.11.1686CrossRefGoogle ScholarPubMed
Hira, T, Pinyo, J, Hara, H. What is GLP-1 really doing in obesity? Trends in Endocrinology & Metabolism. 2020;31(2):71–80. doi:10.1016/j.tem.2019.09.003CrossRefGoogle ScholarPubMed
Müller, TD, Finan, B, Bloom, SR, et al. Glucagon-like peptide 1 (GLP-1). Molecular Metabolism 2019;30:72–130. doi:10.1016/j.molmet.2019.09.010CrossRefGoogle ScholarPubMed
Vilsboll, T, Christensen, M, Junker, AE, Knop, FK, Gluud, LL. Effects of glucagon-like peptide-1 receptor agonists on weight loss: Systematic review and meta-analyses of randomised controlled trials. BMJ 2012;344(jan10 2):d7771–d7771. doi:10.1136/bmj.d7771CrossRefGoogle ScholarPubMed
Wang, JY, Wang, QW, Yang, XY, et al. GLP-1 receptor agonists for the treatment of obesity: Role as a promising approach. Front Endocrinol (Lausanne) 2023;14:1085799. Published 2023 Feb 1. doi:10.3389/fendo.2023.1085799CrossRefGoogle ScholarPubMed
Ishøy, PL, Knop, FK, Broberg, BV, et al. Effect of glp‐1 receptor agonist treatment on body weight in obese antipsychotic‐treated patients with schizophrenia: A randomized, placebo‐controlled trial. Diabetes, Obesity and Metabolism 2016;19(2):162–171. doi:10.1111/dom.12795CrossRefGoogle ScholarPubMed
Maagensen, H, Larsen, JR, Jørgensen, NR, Fink-Jensen, A, Vilsbøll, T. Liraglutide does not change bone turnover in clozapine- and olanzapine-treated schizophrenia overweight patients with prediabetes—Randomized controlled trial. Psychiatry Research 2021;296:113670. doi:10.1016/j.psychres.2020.113670CrossRefGoogle Scholar
Siskind, DJ, Russell, AW, Gamble, C, et al. Treatment of clozapine‐associated obesity and diabetes with exenatide in adults with schizophrenia: A randomized controlled trial (CODEX). Diabetes, Obesity and Metabolism 2017;20(4):1050–1055. doi:10.1111/dom.13167CrossRefGoogle ScholarPubMed
Larsen, JR, Vedtofte, L, Jakobsen, MS, et al. Effect of liraglutide treatment on prediabetes and overweight or obesity in clozapine- or olanzapine-treated patients with schizophrenia spectrum disorder. JAMA Psychiatry 2017;74(7):719. doi:10.1001/jamapsychiatry.2017.1220CrossRefGoogle ScholarPubMed
McElroy, SL, Guerdjikova, AI, Blom, TJ, Mori, N, Romo-Nava, F. Liraglutide in obese or overweight individuals with stable bipolar disorder. Journal of Clinical Psychopharmacology 2024;44(2):89–95. doi:10.1097/jcp.0000000000001803Google ScholarPubMed
Whicher, CA, Price, HC, Phiri, P, et al. The use of liraglutide 3.0 mg daily in the management of overweight and obesity in people with schizophrenia, schizoaffective disorder and first episode psychosis: Results of a pilot randomized, double‐blind, placebo‐controlled trial. Diabetes, Obesity and Metabolism 2021;23(6):1262–1271. doi:10.1111/dom.14334CrossRefGoogle ScholarPubMed
Sterne, JAC, Savovic, J, Page, MJ, et al. RoB 2: A revised tool for assessing risk of bias in randomised trials. The BMJ 2019;366:14898 doi:10.1136/bmj.l48982Google ScholarPubMed
McIntyre, RS. Glucagon-like peptide-1 receptor agonists (GLP-1 RAS) and suicidality: What do we know and Future Vistas. Expert Opinion on Drug Safety 2024;23(5):539–542. doi: 10.1080/14740338.2024.2335215CrossRefGoogle ScholarPubMed
Meissner, WG, Remy, P, Giordana, C, Maltête, D, et al. Trial of lixisenatide in early Parkinson’s disease. The New England Journal of Medicine 2024;390(13):1176–1185. doi:10.1056/NEJMoa2312323CrossRefGoogle ScholarPubMed
Cukierman-Yaffe, T, Gerstein, HC, Colhoun, HM, et al. Effect of dulaglutide on cognitive impairment in type 2 diabetes: An exploratory analysis of the rewind trial. The Lancet Neurology 2024;19(7):582–590. doi:10.1016/S1474-4422(20)30173-3CrossRefGoogle Scholar
Cooper, DH, Ramachandra, R, Ceban, F, et al. Glucagon-like peptide 1 (GLP-1) receptor agonists as a protective factor for incident depression in patients with diabetes mellitus: A systematic review. Journal of Psychiatric Research 2023;164:80–89. doi: 10.1016/j.jpsychires.2023.05.041CrossRefGoogle ScholarPubMed
EMA statement on ongoing review of GLP-1 receptor agonists. European Medicines Agency. 2024. https://www.ema.europa.eu/en/news/ema-statement-ongoing-review-glp-1-receptor-agonists.Google Scholar
Update on FDA’s ongoing evaluation of GLP-1 Ras and Suicidality. U.S. Food and Drug Administration. FDA Center for Drug Evaluation and Research. 2024. https://www.fda.gov/drugs/drug-safety-and-availability/update-fdas-ongoing-evaluation-reports-suicidal-thoughts-or-actions-patients-taking-certain-type#:~:text=Similarly%2C%20our%20reviews%20of%20the,of%20suicidal%20thoughts%20or%20actions.Google Scholar
McIntyre, RS, Mansur, RB, Rosenblat, JD, Kwan, ATH. The association between glucagon-like peptide-1 receptor agonists (GLP-1 RAS) and suicidality: Reports to the Food and Drug Administration Adverse Event Reporting System (FAERS). Expert Opinion on Drug Safety 2024;23(1):47–55. doi: 10.1080/14740338.2023.2295397CrossRefGoogle Scholar
McIntyre, RS, Mansur, RB, Rosenblat, JD, et al. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and suicidality: A replication study using reports to the World Health Organization pharmacovigilance database (VigiBase®). J Affect Disord 2024;369:922–927.CrossRefGoogle Scholar